ArticleScientific reports2026

A murine proof-of-concept study of polatuzumab vedotin in combination with venetoclax in experimental therapy of BCL2-positive aggressive lymphomas.

Eva Pokorna et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.